Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: Histologically* or cytologically* confirmed non-small cell lung cancer Any histology, except squamous cell carcinoma, allowed Mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible No histology in close proximity to a major vessel or cavitation NOTE: *Histologic or cytologic elements may be established on metastatic tumor aspirates or biopsy Meets 1 of the following stage criteria: Stage IIIB disease (with malignant pleural effusion) Stage IV disease Recurrent disease Measurable or non-measurable disease No known CNS metastases by CT scan or MRI PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic Absolute neutrophil count > 1,500/mm^3 Platelet count > 100,000/mm^3 No history of hemorrhagic disorders Hepatic Bilirubin < 1.5 mg/dL AST and ALT < 5 times upper limit of normal INR < 1.5 PTT normal Renal Creatinine clearance ≥ 45 mL/min Urine protein:creatinine ≤ 1.0 by spot urinalysis Cardiovascular No myocardial infarction within the past 6 months No New York Heart Association class II-IV congestive heart failure No unstable angina pectoris No serious cardiac arrhythmia requiring medication No stroke within the past 6 months No peripheral vascular disease ≥ grade 2 No uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg) Patients with a history of hypertension allowed provided blood pressure is well controlled on a stable regimen of anti-hypertensive therapy No history of thrombotic disorders No other clinically significant cardiovascular disease Pulmonary No history of gross hemoptysis, defined as bright red blood of a ½ teaspoon or more Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Must be willing and able to take daily oral folic acid, intermittent vitamin B_12 injections, and corticosteroid premedication No ongoing or active infection No serious, non-healing wound, ulcer, or bone fracture No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months No psychiatric illness or social situation that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy More than 3 weeks since prior immunotherapy Chemotherapy No prior systemic chemotherapy Endocrine therapy More than 3 weeks since prior hormonal therapy Radiotherapy See Disease Characteristics More than 3 weeks since prior radiotherapy Surgery More than 4 weeks since prior major surgery More than 1 week since prior minor surgery, fine needle aspiration, or core biopsy No concurrent major surgery Other Recovered from all prior therapy More than 4 weeks since prior and no concurrent participation in another experimental drug study No aspirin or other nonsteroidal anti-inflammatory drug (NSAID) 2 days before and 2 days after each pemetrexed disodium infusion (5 days before and 2 days after each pemetrexed disodium infusion for NSAIDs with a long half-life [e.g., naproxen, rofecoxib, or celecoxib]) No concurrent therapeutic anticoagulation Concurrent prophylactic anticoagulation for venous access devices allowed provided requirements for INR and PTT are met No concurrent administration of any of the following: Chronic daily treatment with aspirin (> 325 mg per day) NSAIDs known to inhibit platelet function, including any of the following: Dipyridamole Ticlopidine Clopidogrel Cilostazol